BIOMAT Database Logo BIOMAT Database Logo

[Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi]. 1992

M J Gevaudan, and C Bollet, and M N Mallet, and X de Lamballerie, and R Sambuc, and P de Micco
Laboratoire de Microbiologie, Hôpital Salvator, Marseille.

Activity of the new fluoroquinolone sparfloxacin against 30 strains of M. avium complex and 25 strains of M. xenopi was tested in vitro. Sparfloxacin was used alone (determination of MICs and MBCs) and in combination with ethambutol and rifabutin. Synergy studies with determination of the FIC and FBC indices showed that the sparfloxacin-ethambutol combination was synergistic against 10 M. avium complex strains and 12 M. xenopi strains. With the three-drug combination (sparfloxacin-ethambutol-rifabutin), synergy was found against 12 M. avium and 14 M. xenopi strains. Studies of intracellular bacteria showed that the decrease in viable bacteria with the three-drug combination was 1 log for M. avium and 2 log for M. xenopi.

UI MeSH Term Description Entries
D009161 Mycobacterium A genus of gram-positive, aerobic bacteria. Most species are free-living in soil and water, but the major habitat for some is the diseased tissue of warm-blooded hosts. Mycobacteria
D009164 Mycobacterium Infections Infections with bacteria of the genus MYCOBACTERIUM. Infections, Mycobacterium,Infection, Mycobacterium,Mycobacterium Infection
D009894 Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression. Infection, Opportunistic,Infections, Opportunistic,Opportunistic Infection
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004977 Ethambutol An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863) Dexambutol,EMB-Fatol,EMB-Hefa,Etambutol Llorente,Ethambutol Hydrochloride,Etibi,Miambutol,Myambutol,EMB Fatol,EMB Hefa,Hydrochloride, Ethambutol,Llorente, Etambutol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012294 Rifamycins A group of ANTI-BACTERIAL AGENTS characterized by a chromophoric naphthohydroquinone group spanned by an aliphatic bridge not previously found in other known ANTI-BACTERIAL AGENTS. They have been isolated from fermentation broths of Streptomyces mediterranei. Rifamycin,Rifomycin,Rifomycins

Related Publications

M J Gevaudan, and C Bollet, and M N Mallet, and X de Lamballerie, and R Sambuc, and P de Micco
Activity of five fluoroquinolones against Mycobacterium avium-intracellulare complex and M. xenopi.
January 1988, Annales de l'Institut Pasteur. Microbiology,
M J Gevaudan, and C Bollet, and M N Mallet, and X de Lamballerie, and R Sambuc, and P de Micco
Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin.
November 1996, Antimicrobial agents and chemotherapy,
M J Gevaudan, and C Bollet, and M N Mallet, and X de Lamballerie, and R Sambuc, and P de Micco
Intracellular activity of azithromycin against Mycobacterium avium complex in human macrophages.
July 1997, Arzneimittel-Forschung,
M J Gevaudan, and C Bollet, and M N Mallet, and X de Lamballerie, and R Sambuc, and P de Micco
Antibacterial activity and clinical efficacy of sparfloxacin in Mycobacterium avium-intracellulare complex infection.
January 2004, The Journal of international medical research,
M J Gevaudan, and C Bollet, and M N Mallet, and X de Lamballerie, and R Sambuc, and P de Micco
[Extra and intracellular activity of dirithromycin against Mycobacterium avium].
April 1995, Pathologie-biologie,
M J Gevaudan, and C Bollet, and M N Mallet, and X de Lamballerie, and R Sambuc, and P de Micco
Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones.
January 2006, The Journal of antimicrobial chemotherapy,
M J Gevaudan, and C Bollet, and M N Mallet, and X de Lamballerie, and R Sambuc, and P de Micco
Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages.
March 1996, The Journal of antimicrobial chemotherapy,
M J Gevaudan, and C Bollet, and M N Mallet, and X de Lamballerie, and R Sambuc, and P de Micco
[Intracellular killing mechanisms of alveolar macrophages against Mycobacterium avium complex].
January 1992, Kekkaku : [Tuberculosis],
M J Gevaudan, and C Bollet, and M N Mallet, and X de Lamballerie, and R Sambuc, and P de Micco
In-vitro activity of oxazolidinones against Mycobacterium avium complex.
May 1995, The Journal of antimicrobial chemotherapy,
M J Gevaudan, and C Bollet, and M N Mallet, and X de Lamballerie, and R Sambuc, and P de Micco
[Bactericidal activity of antituberculosis drugs against Mycobacterium avium complex].
January 1990, Kekkaku : [Tuberculosis],
Copied contents to your clipboard!